Oric Pharmaceuticals Inc (ORIC) Live Share Price, Invest From India

Oric Pharmaceuticals Inc Stock Performance

as on April 18, 2026 at 6:59 am IST

Day's Low
Day's High
$10.30
Day's Price Range
$10.98
$10.74
4.10%
Downside
2.23%
Upside
52 Week's Low
52 Week's High
$4.52
52-Week Price Range
$14.93
$10.74
57.91%
Downside
39.01%
Upside

Oric Pharmaceuticals Inc share price movements today

Previous Close: $10.23
Open: $10.42
Volume: 1.6M
Day's Low - High: $10.30 - $10.98
52 Week Low - High: $4.52 - $14.93

Oric Pharmaceuticals Inc Historical Returns

1 Month Return: -15.24 %
3 Month Return: -15.59 %
1 Year Return: + 114.47 %
3 Year Return: + 66.34 %
5 Year Return: -52.04 %

Oric Pharmaceuticals Inc Stock Fundamentals & Key Indicators

Check Oric Pharmaceuticals Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$1.2B

EPS (TTM)

-1.4032

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

PEG Ratio

EBITDA

-141.8M

Revenue (TTM)

Profit Margin

0.00%

Return On Equity TTM

-41.27%

Oric Pharmaceuticals Inc vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Oric Pharmaceuticals Inc with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %
Oric Pharmaceuticals Inc	BUY	$1.2B	-52.04%	NA	0.00%
Alnylam Pharmaceuticals Inc	BUY	$42.7B	130.51%	136.81	8.45%
Vertex Pharmaceuticals Inc	BUY	$110.8B	98.57%	28.42	32.94%
BeiGene, Ltd.	NA	$36.8B	NA	129.84	5.37%
Regeneron Pharmaceuticals Inc	BUY	$78.9B	48.43%	17.98	31.41%

Stock Returns calculator for Oric Pharmaceuticals Inc Stock including INR - Dollar returns

The Oric Pharmaceuticals Inc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

Oric Pharmaceuticals Inc investment value today

Current value as on today

₹2,44,612

Returns

₹1,44,612

(+144.61%)

Returns from Oric Pharmaceuticals Inc Stock

₹1,25,157 (+125.16%)

Dollar Impact

₹19,454 (+19.45%)

Analyst Recommendation on Oric Pharmaceuticals Inc Stock

Based on 15 analysts

BUY

93.33%

Buy

6.67%

Hold

0.00%

Sell

Based on 15 analysts, 93.33% of analysts recommend a 'BUY' rating for Oric Pharmaceuticals Inc. Average target price of $21

Oric Pharmaceuticals Inc Share Price Target

Get share price movements and forecasts by analysts on Oric Pharmaceuticals Inc.

What analysts predicted

48.86%UPSIDE

Target Price

$21

Current Price

$10.74

Analyzed by

15 Analysts

Target

$21.00

Oric Pharmaceuticals Inc target price $21, a slight upside of 48.86% compared to current price of $10.74. According to 15 analysts rating.

Oric Pharmaceuticals Inc Stock’s Investor Sentiment and Interest

Search interest for Oric Pharmaceuticals Inc Stock has increased by 9% in the last 30 days, reflecting an upward trend in search activity.

Time period: March 19, 2026 to April 18, 2026

Change:9% versus previous 30 day period

Oric Pharmaceuticals Inc Quarterly Profit & Loss

All numbers in Millions USD

	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Total Revenue	-	1	-	-	-	1	-	-	-	-
Gross Profit	0	0	0	0	0	0	0	0	-	0
Operating Income	-28	-31	-28	-36	-38	-39	-32	-39	-36	-34
EBITDA	-28	-28	-28	-35	-38	-36	-32	-38	-32	-30
Interest Expense	-	1	-	-	-	-	-	-	-	-
Depreciation	0	0	0	0	0	0	0	0	0	0
Income Before Tax	-25	-28	-25	-31	-34	-36	-30	-36	-32	-30
Income Tax Expense	0	2	0	0	-	-	-	-	-	-
Net Income	-25	-28	-25	-31	-34	-36	-30	-36	-32	-30
Net Profit Margin	0.00%	-1842.00%	0.00%	0.00%	0.00%	-3405.91%	0.00%	0.00%	0.00%	0.00%

Oric Pharmaceuticals Inc Annual Profit & Loss

All numbers in Millions USD

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Revenue	-	-	-	-	-	-	-	-
Gross Profit	0	-1	0	0	0	-1	-1	-1
Operating Income	-22	-28	-74	-78	-91	-110	-142	-143
EBITDA	-20	-25	-48	-77	-85	-109	-126	-128
Interest Expense	1	1	0	0	2	-	-	-
Depreciation	0	1	0	0	0	1	1	1
Income Before Tax	-21	-26	-73	-78	-89	-100	-127	-129
Income Tax Expense	-1	-1	23	-1	2	-	-	-
Net Income	-21	-26	-73	-77	-89	-100	-127	-129
Net Profit Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Oric Pharmaceuticals Inc Quarterly Cash Flow

All numbers in Millions USD

	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Net Income	-28	-25	-31	-34	-36	-30	-36	-32	-30
Operating Cash Flow	-24	-30	-25	-28	-28	-32	-30	-25	-22
Investing Cash Flow	20	-61	18	23	42	22	-76	-110	16
Financing Cash Flow	0	125	0	0	0	0	134	109	1
Change in Cash	-2	32	-6	-5	15	-10	26	-26	-3

Oric Pharmaceuticals Inc Annual Cash Flow

All numbers in Millions USD

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Net Income	-21	-26	-73	-78	-89	-100	-127	-129
Operating Cash Flow	-20	-23	-45	-59	-75	-85	-112	-113
Investing Cash Flow	0	0	-215	158	-109	-43	22	-148
Financing Cash Flow	38	70	250	49	25	85	126	247
Change in Cash	16	46	-10	148	-159	-43	36	-13

Global Institutional Holdings in Oric Pharmaceuticals Inc

Funds	Holdings
SR ONE CAPITAL MANAGEMENT, LP	4.03%
NEA Management Company, LLC	3.68%
FMR Inc	2.21%
JPMorgan Chase & Co	2.19%
EcoR1 Capital, LLC	6.01%

See all

Insights on Oric Pharmaceuticals Inc

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

POSITIVE IMPACT
Best in 1 Year
In the last 1 year, ORIC has outperformed top 5 stocks with highest market-cap in its industry
POSITIVE IMPACT
Best in 3 Years
In the last 3 years, ORIC has outperformed top 5 stocks with highest market-cap in its industry
NEGATIVE IMPACT
Price Dip
In the last 1 month, ORIC stock has moved down by -5.8%

About Oric Pharmaceuticals Inc

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its clinical stage product candidates include enozertinib formerly known as ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency towards exon 20 insertion mutations; and rinzimetostat formerly known as ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study. It has a clinical trial collaboration and supply agreement with Bayer to evaluate ORIC-944 in combination with Nubeqa AR inhibitor; and a clinical trial collaboration and supply agreement with Johnson & Johnson to evaluate ORIC 944 in combination with Erleada AR inhibitor. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

Organisation	Oric Pharmaceuticals Inc
Headquarters	240 E. Grand Ave, South San Francisco, CA, United States, 94080
Industry	Biotechnology
CEO	Dr. Jacob M. Chacko M.B.A., M.D.
E-voting on shares	Click here to vote

Key Management of Oric Pharmaceuticals Inc

Name	Title
Dr. Scott W. Lowe Ph.D.	Founder & Member of Scientific Advisory Board
Dr. Lori Sickels Friedman Ph.D.	Chief Scientific Officer
Dr. Christian V. Kuhlen Esq., J.D., M.D.	General Counsel
Mr. Daniel Iazzetti	VP & Head of People
Dr. Edna Chow Maneval Ph.D.	Executive Vice President of Clinical Development
Dr. Richard A. Heyman Ph.D.	Founder, Independent Chairman & Member of Scientific Advisory Board
Dr. Jacob M. Chacko M.B.A., M.D.	President, CEO & Director
Dr. Pratik S. Multani M.D., M.S.	Chief Medical Officer
Dr. Charles L. Sawyers B.A., M.D., Ph.D.	Founder & Member of Scientific Advisory Board
Dr. Kevin Brodbeck Ph.D.	Chief Technical Officer

FAQs

What is Oric Pharmaceuticals Inc share price today?

Oric Pharmaceuticals Inc share price today is $10.74 as on April 18, 2026 at 1:29 am IST at the close of the market. Oric Pharmaceuticals Inc share today touched a day high of $10.98 and a low of $10.3.

What is the 52 week high and 52 week low for Oric Pharmaceuticals Inc share?

Oric Pharmaceuticals Inc share touched a 52 week high of $14.93 on October 7, 2025 and a 52 week low of $4.52 on May 7, 2025. Oric Pharmaceuticals Inc stock price today i.e. April 18, 2026 at 1:29 am IST is closed at $10.74,which is 28.06% down from its 52 week high and 137.61% up from its 52 week low.

What is Oric Pharmaceuticals Inc's market capitalisation today?

Oric Pharmaceuticals Inc market capitalisation is $0.00T as on April 18, 2026 at 1:29 am IST.

How to invest in Oric Pharmaceuticals Inc Stock (ORIC) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Oric Pharmaceuticals Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Oric Pharmaceuticals Inc Shares that will get you 0.1397 shares as per Oric Pharmaceuticals Inc share price of $10.74 per share as on April 18, 2026 at 1:29 am IST.

What is the minimum amount required to buy Oric Pharmaceuticals Inc Stock (ORIC) from India?

Indian investors can start investing in Oric Pharmaceuticals Inc (ORIC) shares with as little as ₹92.768 or $1 (as of April 18, 2026 at 9:38 am IST) using the INDmoney app.
For example: If you want to invest $10 or ₹927.68 in Oric Pharmaceuticals Inc stock (as per the Rupee-Dollar exchange rate as on April 18, 2026 at 9:38 am IST). Based on Oric Pharmaceuticals Inc share’s latest price of $10.74 as on April 18, 2026 at 1:29 am IST, you will get 0.9311 shares of Oric Pharmaceuticals Inc. Learn more about fractional shares .

What are the returns that Oric Pharmaceuticals Inc has given to Indian investors in the last 5 years?

Oric Pharmaceuticals Inc stock has given -52.04% share price returns and 24.45% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?